Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284616 | 0.84 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL13437617 | 0.84 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL4809435 | 0.81 | PIK3CA (0.67) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL10068886 | 0.81 | PIK3CG (0.60) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL31061504 | 0.80 | PIK3CG (0.62) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL4808710 | 0.79 | PIK3CG (0.64) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL909904 | 0.79 | PIK3CG (0.71) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL13752239 | 0.78 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL4412270 | 0.78 | PIK3CG (0.83) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 | |
| SCHEMBL4415711 | 0.78 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| EP-1869040-A1 | DNA-PK INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1869021-A1 | DNA-PK INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| US-20060264623-A1 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| WO-2006109081-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109084-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264623-A1 | DNA-PK inhibitors | TOP2B, TOP2A, POLN | PIK3CG 1506/4885PIK3CA 1074/4885PIK3CD 1343/4885 |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | POLK, DCK, POLN | PIK3CG 1941/4885PIK3CA 1723/4885PIK3CD 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.